Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT01342354
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Stereotactic Radiation 10 Gy — RADIATION
    10 Gy three times over 10 days
  • Stereotactic Radiation 12.5 Gy — RADIATION
    12.5 Gy three times over 10 days
  • Stereotactic Radiation 15 Gy — RADIATION
    15 Gy three times over 10 days

Study Details

This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.

Key Dates

Start date
Apr 14, 2009
Status verified
Jun 2025
Primary completion
Aug 31, 2020
Completion
Jun 1, 2022

Study Design

Enrollment
15 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Stereotactic Radiation: 10 Gy x3
    Level 1 - SBRT 10Gy in three doses over ten days (total 30 Gy).
  • Experimental: Stereotactic Radiation: 12.5 Gy x3
    Level 2 - SBRT 12.5Gy in three doses over ten days (total 37.5 Gy).
  • Experimental: Stereotactic Radiation: 15 Gy x3
    Level 3 - SBRT 15Gy in three doses over ten days (total 45 Gy).

Primary Outcome Measure

Maximum Tolerated Dose (Phase 1) [ Time Frame: 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637-

Find similar trials in Chicago, IL

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Chicago· Chicago, IL

Related Studies